Abstract
Acquired factor V deficiency (AFVD) is a rare autoimmune bleeding disorder. Unlike acquired hemophilia, bypass therapies with recombinant activated factor VII and activated prothrombin complex concentrates are ineffective for severe bleeding due to AFVD. Although several treatment strategies have been attempted, a standard of care for severe hemorrhage induced by AFVD is lacking. Herein, we report a case of AFVD with severe bleeding that responded to plasma exchange (PE) combined with immunosuppression. We also reviewed previously reported AFVD cases with severe hemorrhage and suggest that PE may be an effective initial treatment for AFVD-induced severe hemorrhage.
References
1.
Knöbl
P
, Lechner
K
. Acquired factor V inhibitors
. Baillieres Clin Haematol
. 1998
Jun
;11
(2
):305
–18
.
[PubMed]
0950-35362.
Franchini
M
, Lippi
G
. Acquired factor V inhibitors: a systematic review
. J Thromb Thrombolysis
. 2011
May
;31
(4
):449
–57
.
[PubMed]
0929-53053.
Wang
X
, Qin
X
, Yu
Y
, Wang
R
, Liu
X
, Ji
M
, et al. Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature
. Blood Coagul Fibrinolysis
. 2017
Jun
;28
(4
):334
–41
.
[PubMed]
0957-52354.
Kunimoto
H
, Miyakawa
Y
, Okamoto
S
. Acquired factor V deficiency and mini literature review
. Haemophilia
. 2012
May
;18
(3
):e86
–7
.
[PubMed]
1351-82165.
Gavva
C
, Yates
SG
, Rambally
S
, Sarode
R
. Transfusion management of factor V deficiency: three case reports and review of the literature
. Transfusion
. 2016
Jul
;56
(7
):1745
–9
.
[PubMed]
0041-11326.
Hirai
D
, Yamashita
Y
, Masunaga
N
, Katsura
T
, Akao
M
, Okuno
Y
, et al. Acquired Factor V Inhibitor
. Intern Med
. 2016
;55
(20
):3039
–42
.
[PubMed]
0918-29187.
Patel
MD
, Hajdenberg
J
. Successful treatment of chronic recurrent life-threatening bleeding due to an acquired factor V Inhibitor with rituximab and steroids
. Haemophilia
. 2016
May
;22
(3
):e231
–2
.
[PubMed]
1351-82168.
Leung
AK
, Ng
GW
, Sin
KC
, Au
SY
, Lai
KY
, Lee
KL
, et al. Acquired factor V inhibitor in a patient receiving venous-venous extracorporeal membrane oxygenation for Legionella pneumonia
. Hong Kong Med J
. 2015
Apr
;21
(2
):175
–8
.
[PubMed]
1024-27089.
Yamada
Y
, Miyakawa
Y
, Sawano
M
, Okano
Y
. Successful treatment of severe lung hemorrhage caused by acquired factor V inhibitor with rituximab
. Intern Med
. 2014
;53
(10
):1083
–5
.
[PubMed]
0918-291810.
Ahmadinejad
M
, Roushan
N
. Acquired factor V inhibitor developing in a patient with esophageal squamous cell carcinoma
. Blood Coagul Fibrinolysis
. 2013
Jan
;24
(1
):97
–9
.
[PubMed]
0957-523511.
Ciang
CO
, Leung
MH
. Acquired factor V inhibitor in systemic vasculitis
. Int J Rheum Dis
. 2012
Apr
;15
(2
):e19
–22
.
[PubMed]
1756-184112.
Morris
CJ
, Curry
N
. Acquired factor V inhibitor in a critically ill patient
. Anaesthesia
. 2009
Sep
;64
(9
):1014
–7
.
[PubMed]
0003-240913.
Denier
C
, Bouteredjiret
T
, Dreyfus
M
, Lacroix
C
, Adams
D
. Late and fatal deterioration of an intracerebral hemorrhage attributable to the onset of a high titer of acquired factor V inhibitor
. Eur Neurol
. 2008
;60
(4
):206
–7
.
[PubMed]
0014-302214.
Lebrun
A
, Leroy-Matheron
C
, Arlet
JB
, Bartolucci
P
, Michel
M
. Successful treatment with rituximab in a patient with an acquired factor V inhibitor
. Am J Hematol
. 2008
Feb
;83
(2
):163
–4
.
[PubMed]
0361-860915.
de Raucourt
E
, Barbier
C
, Sinda
P
, Dib
M
, Peltier
JY
, Ternisien
C
. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors
. Am J Hematol
. 2003
Nov
;74
(3
):187
–90
.
[PubMed]
0361-860916.
Ajzner
E
, Balogh
I
, Haramura
G
, Boda
Z
, Kalmár
K
, Pfliegler
G
, et al. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding
. J Thromb Haemost
. 2003
May
;1
(5
):943
–9
.
[PubMed]
1538-793317.
Takahashi
H
, Fuse
I
, Abe
T
, Yoshino
N
, Aizawa
Y
. Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy
. Blood Coagul Fibrinolysis
. 2003
Jan
;14
(1
):87
–93
.
[PubMed]
0957-523518.
Emori
Y
, Sakugawa
M
, Niiya
K
, Kiguchi
T
, Kojima
K
, Takenaka
K
, et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis
. Blood Coagul Fibrinolysis
. 2002
Sep
;13
(6
):555
–9
.
[PubMed]
0957-523519.
Tarantino
MD
, Ross
MP
, Daniels
TM
, Nichols
WL
. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin
. J Pediatr Hematol Oncol
. 1997
May-Jun
;19
(3
):226
–31
.
[PubMed]
1077-411420.
Fu
YX
, Kaufman
R
, Rudolph
AE
, Collum
SE
, Blinder
MA
. Multimodality therapy of an acquired factor V inhibitor
. Am J Hematol
. 1996
Apr
;51
(4
):315
–8
.
[PubMed]
0361-8609© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
